Sinovac Biotech (SVA) Stock Price, Quote, News & History | Benzinga

SPY779.87+0.10%QQQ759.84+0.02%BTC/USD85,495.75−0.06%DIA514.66+0.02%GLD381.90−0.10%TLT77.20−0.10%

Sinovac Biotech Ltd (SVA) Stock Price, Quote, News & History

SVANASDAQ

Trade with Public

Trade with Public

$5.85

Last update: Dec 24, 9:29 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Stock Report

Key Statistics

Open

-

Close

-

Volume / Avg.

0 / -

Day Range

- - -

52 Wk Range

- - -

Market Cap

$420.39M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

-

Short Interest

-

Days to Cover

999.99

Recent Sinovac Biotech Ltd News

CSPC Pharma Wins China's mRNA Vaccine Race, But Just Not Fast Enough

Key Takeaways: News of marketing approval for China’s first mRNA vaccine falls flat with investors, who worry the drug is being rushed to market before Phase 3 trials are complete As the pandemic abates, the market for the vaccine is shrinking rapidly By Ellie Si

The Bamboo Works

Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It

COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.

Adam Eckert

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Vandana Singh

Which COVID-19 Vaccine(s) Significantly Prevented Deaths - Read To Find Out

Vandana Singh

CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited benefits for the company as the pandemic fades and other products are widely available By Jony Ho

The Bamboo Works

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-566.03M

Investing Cash Flow (TTM)

716.40M

Financing Cash Flow (TTM)

-3.42B

Free Cash Flow (TTM)

-608.34M

Capital Expenditure (TTM)

-42.31M

Net Change in Cash (TTM)

-3.27B

Analyst Trends and Forecast

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$297.09M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-

Company Debt

Total Debt

$381.17M

LT Debt

$233.12M

LT Debt Issuance (TTM)

$137.21M

LT Debt Repayment (TTM)

-$228.91M

Total Cash

$322.26M

Debt to Equity

0.09

Issuance of Debt (TTM)

-$91.71M

Repayment of Debt (TTM)

-$228.91M